METAZ 0.1% OINTMENT 30G

Indications

Approved Uses

Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis and psoriasis).

Off-Label Uses

Off-label uses may include alopecia areata, vitiligo (adjunct), lichen planus (cutaneous), and prurigo nodularis; phimosis is more commonly supported with other topical steroids and is not a typical mometasone-specific off-label use.

Dosage & Administration

Dosing by Condition

For corticosteroid-responsive dermatoses (including eczema/atopic dermatitis and psoriasis): apply a thin layer to affected areas once daily; occlusion is generally avoided and, if considered for resistant psoriasis, should only be under clinician supervision.

Initial Dose

Apply a thin film to the affected skin areas once daily.

Maintenance Dose

Apply a thin film to the affected skin areas once daily. Therapy should be discontinued when control is achieved.

Maximum Dose

Apply a thin film once daily; no universally fixed gram/week maximum is established for mometasone ointment-limit to the smallest amount needed and avoid large surface areas, prolonged continuous use, or occlusion unless directed.

Children's Dosage

For children 2 years of age and older, apply a thin film to the affected area once daily. Use for longer than 3 weeks has not been established. Not recommended for use in children under 2 years of age.

Dose Adjustment Notes

Use the lowest effective amount for the shortest duration; reassess if no improvement within ~2 weeks; once controlled, step down by reducing frequency (e.g., alternate days/2-3 times weekly) and avoid prolonged continuous use, especially on face/intertriginous areas or large surface areas and under occlusion.

How to Take

For topical use only: apply a thin layer to affected skin once daily and rub in gently; wash hands before and after (unless treating hands); avoid eyes, mouth, and other mucous membranes; do not use on face/groin/axillae or under occlusion/bandages unless directed by a clinician.

Side Effects

Common Side Effects

Application-site burning/stinging, pruritus, irritation/dryness/erythema; folliculitis/acneiform eruption; with prolonged use: skin atrophy, striae, telangiectasia, hypopigmentation, and contact dermatitis; secondary infection may occur.

Side Effect Frequency

Common: application-site burning/stinging, pruritus, irritation/dryness. Less common/uncommon: folliculitis, acneiform eruptions, perioral dermatitis, hypopigmentation, hypertrichosis, allergic contact dermatitis, secondary infection, skin atrophy, striae, telangiectasia, miliaria. Rare/with prolonged use, large areas, or occlusion: HPA-axis suppression/Cushingoid effects, hyperglycemia; ocular effects (blurred vision, glaucoma, cataract) have been reported particularly with periocular use.

Safety & Warnings

Contraindications

Contraindicated in hypersensitivity to mometasone furoate or excipients; avoid use on untreated bacterial/viral (e.g., herpes simplex/varicella)/fungal/parasitic skin infections; avoid use in rosacea, perioral dermatitis, and acne vulgaris.

Warnings & Precautions

Avoid eyes/mucosa; do not use under occlusion unless directed; avoid/limit use on face, groin, axillae and do not use for diaper dermatitis; do not apply to infected lesions without appropriate antimicrobial therapy; use the lowest effective amount/shortest duration and consider tapering after long-term use; pediatric patients are at higher risk of systemic toxicity; monitor for skin atrophy and visual symptoms.

Age Restriction

Not recommended for children <2 years; in ≥2 years use the lowest effective amount for the shortest duration.

Driving Warning

Safe

Drug Interactions

Drug Interactions

Clinically relevant interactions are uncommon, but systemic exposure may increase with strong CYP3A inhibitors (e.g., ritonavir/cobicistat/itraconazole/ketoconazole) if absorption is significant; occlusive dressings and concurrent potent topical steroids increase systemic absorption risk.

Interaction Severity

MODERATE: strong CYP3A4 inhibitors (e.g., ritonavir/cobicistat, ketoconazole, itraconazole) may increase systemic corticosteroid effects if significant percutaneous absorption occurs (large areas, prolonged use, occlusion).

Food Interaction

No restriction

Alcohol Interaction

Safe

Special Populations

Pregnancy

Category C

Breastfeeding

Caution

Children

For children 2 years of age and older, apply a thin film to the affected area once daily. Use for longer than 3 weeks has not been established. Not recommended for use in children under 2 years of age.

Elderly

Standard adult dosing; use with caution as elderly skin is more susceptible to atrophy and systemic absorption

Kidney Impairment

No adjustment needed

Liver Impairment

No dose adjustment recommended; use caution with extensive/prolonged use in severe hepatic impairment because systemic corticosteroid exposure could be higher if absorbed.

Storage & Patient Advice

Storage Conditions

Store below 25°C (per SFDA verified API data); keep the tube tightly closed and do not freeze.

Missed Dose

Apply when remembered; if it is close to the next scheduled application, skip the missed dose and resume the regular schedule-do not apply extra to make up for it.

Stopping the Medicine

Stop when control is achieved; if used long-term, on large areas, or under occlusion, taper (reduce frequency/potency) rather than abrupt cessation to reduce rebound/withdrawal and adrenal suppression risk.

Overdose

Excessive/prolonged topical use (especially large areas/occlusion) can cause local adverse effects and systemic corticosteroid toxicity including HPA-axis suppression/Cushingoid features; management is to stop or taper and provide supportive care; if ingested, contact poison control/seek medical care.

Patient Counseling

For topical use only for the prescribed condition. Apply a thin film to affected skin once daily (or as directed) and rub in gently; use the smallest amount for the shortest duration. Avoid eyes, mouth, and mucous membranes; wash hands after use unless treating hands. Do not use on the face, groin, or axillae, on broken/infected skin, or under occlusion (tight bandages/diapers) unless specifically directed. Stop and seek medical advice if irritation, worsening, or signs of infection occur, or if no improvement within ~2 weeks (or as advised). Keep out of reach of children.

Monitoring Requirements

Monitor clinical response and local adverse effects (atrophy, striae, telangiectasia, irritation, secondary infection); in higher-risk use (large surface area, prolonged therapy, occlusion, pediatric patients), periodically evaluate for HPA-axis suppression.

Pharmacology

Mechanism of Action

Topical glucocorticoid: binds intracellular glucocorticoid receptors to alter gene transcription, inducing lipocortins that inhibit phospholipase A2 and downstream prostaglandin/leukotriene production, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.

Onset of Action

Within a few days

Duration of Effect

Up to 24 hours

Half-Life

Not well characterized after topical administration; a definitive systemic half-life is generally not provided for topical mometasone furoate due to minimal absorption.

Bioavailability

Systemic absorption after topical application is low; in studies of 0.1% ointment, about ~0.7% of the applied dose may be absorbed through intact skin, and absorption increases with inflammation, barrier disruption, large surface area, prolonged use, or occlusion.

Metabolism

Any absorbed mometasone furoate is extensively metabolized in the liver to multiple inactive metabolites (CYP3A4 involvement is plausible but not consistently specified as the definitive pathway in standard product information).

Excretion

For the small absorbed fraction, metabolites are eliminated mainly via bile/feces with a minor renal component; timing such as 'within 72 hours' is not a standard, reliably stated parameter for this product.

Protein Binding

Not reliably established/commonly reported for topical mometasone furoate in standard product information; do not state a precise % binding for this product.

Product Information

Available Dosage Forms

Ointment, cream, lotion (and some markets also have topical solution for scalp).

Composition per Dose

Each gram of ointment: 1 mg mometasone furoate (0.1% w/w) in a white petrolatum base

Generic Availability

Yes

OTC Alternatives

No OTC equivalent to mometasone 0.1% potency; for mild disease, OTC hydrocortisone 0.5-1% cream/ointment can be used short-term if appropriate.

Skin Condition

Eczema, Psoriasis

Steroid Potency

Potent

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.